Telaprevir for the treatment of hepatitis C

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 4, 2012, Pages 593-606

  Forestier, Nicole ^a   Zeuzem, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Antiviral therapy; Chronic hepatitis C; Direct antiviral agent (DAA); HCV protease inhibitor; Peginterferon ; Ribavirin; Telaprevir

Indexed keywords

ALFUZOSIN; ATAZANAVIR; ATORVASTATIN; BOCEPREVIR; CISAPRIDE; CYTOCHROME P450 3A; DARUNAVIR; DIHYDROERGOTAMINE; EFAVIRENZ; EMTRICITABINE; ERGOMETRINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; METHADONE; METHYLERGOMETRINE; MEVINOLIN; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PEGINTERFERON ALPHA2A; PIMOZIDE; RALTEGRAVIR; RIBAVIRIN; RIFAMPICIN; SIMVASTATIN; STEROID; TADALAFIL; TELAPREVIR; TENOFOVIR; VIRUS PROTEIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4+ T LYMPHOCYTE; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; GASTROINTESTINAL DISEASE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE CYCLE; LIVER FIBROSIS; MIXED INFECTION; MONOTHERAPY; NAUSEA; PROTEIN STRUCTURE; PRURITUS; RASH; REVIEW; SIDE EFFECT; STANDARD; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS GENOME; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN;

EID: 84857328048     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.660524     Document Type: Review

References (36)

1. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65 (Pubitemid 32913521)
3. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-9.Erratum in: J Hepatol 2005;42:434 (Pubitemid 38670134)
4. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62 (Pubitemid 19117877)
5. Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 2004;63:71-180 (Pubitemid 39752303)
6. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007;5:453-63 (Pubitemid 46780082)
7. De Francesco R, Carfi A. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv Drug Deliv Rev 2007;59:1242-62 (Pubitemid 350047514)
8. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;131:997-1002 (Pubitemid 44498690)
9. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX- 950) and peginterferon alpha-2a in patients with hepatitis C. Hepatology 2007;46:640-8 (Pubitemid 47436108)
10. Forestier N, Susser S, Welker MW, et al. Long term follow-up of patients previously treated with telaprevir: [abstract 1011]. Hepatology 2008;48(Suppl):760A
11. Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alpha-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008;49:163-9
12. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-38.Erratum in: N Engl J Med 2009;361:1516
13. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50
14. Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 h with ribavirin and peginterferon alpha-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011;140:459-68
15. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-303.Erratum in: N Engl J Med 2010;362:1647
16. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16
17. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-24.Erratum in: N Engl J Med 2011;365:1551
18. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28
19. Foster GR, Hezode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011;141:881-9
20. Benhamou Y, Moussalli J, Ratziu V, et al. Activity of telaprevir monotherapy or in combination with peginterferon-alpha-2a and ribavirin in treatment naive genotype 4 hepatitis C patients: final results of study C210 [abstract 828]. Hepatology 2010;52(Suppl):719A
21. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767-77 (Pubitemid 46677938)
22. Lin C, Gates CA, Rao BG, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005;280:36784-91
23. Lin K, Perni RB Kwong AD, et al. VX- 950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob Agents Chemother 2006;50:1813-22
24. Sullivan JC, De Meyer S, Bartels DJ, et al. Evolution of treatment-emergent resistant variants in telaprevir phase III clinical trials [abstract 8]. J Hepatol 2011;54(Suppl 1):S4
25. McCown MF, Rajyaguru S, Kular S, et al. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009;53:2129-32
26. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
27. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9
28. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4
29. Jacobson IM, Catlett I, Marcellin P, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial [abstract 1369]. J Hepatol 2011;54(Suppl 1):S542-3
30. Pol S, Aerssens J, Zeuzem S, et al. Similar SVR rates in IL28B CC, CT or TT prior relapsers, partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the REALIZE study [abstract 13]. J Hepatol 2011;54(Suppl 1):S6-7
31. Incivek- package insert. Cambridge, MA: Vertex Pharmaceuticals, Inc. 12 February 2012. Available from: http://pi.vrtx.com/files/uspi-telaprevir.pdf
32. van Heeswijk R, Vandevoorde A, Verboven P, et al. The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir [abstract 1244]. J Hepatol 2011;54(Suppl 1):S491-2
33. van Heeswijk R, Vandevoorde A, Boogaerts G, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers [abstract 119]. Presented at the 18th Conference on Retroviruses and Opportunistic Infections (CROI); 27 February - 2 March 2011; Boston, MA, USA
34. van Heeswijk R, Garg V, Boogarts G, et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers [abstract A1.1738a]. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 17 - 20 September 2011; Chicago, IL, USA
35. Di Bisceglie AM, Nelson DR, Gane E, et al. VX-222 with TVR alone or in combination with peginterferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C: ZENITH study interim results [abstract 1363]. J Hepatol 2011;54(Suppl 1):S540
36. Sulkowski M, Dieterich D, Sherman K, et al. Interim analysis of a phase IIa double-blind study of TVR in combination with pegIFN-alpha-2a and RBV in HIV/HCV co-infected patients [abstract 146LB]. Presented at the 18th Conference on Retroviruses and Opportunistic Infections (CROI); 27 February - 2 March 2011; Boston, MA, USA